SCHEMBL109215

SCHEMBL109215

O=C(O)Cc1c(Cl)cccc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 1.00
KMT2A Q03164 4/20 0.55
ADRA2A P08913 2/20 0.55
ADRA1A P35348 2/20 0.55
MEN1 O00255 2/20 0.55
LMNA P02545 1/20 0.55
CYP3A4 P08684 1/20 0.55
HTR1A P08908 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
ADRA2B P18089 1/20 0.55
ADRA2C P18825 1/20 0.55
MAOA P21397 1/20 0.55
ADRA1D P25100 1/20 0.55
HTR2A P28223 1/20 0.55
HTR2C P28335 1/20 0.55
MAPK1 P28482 1/20 0.55
CYP2C19 P33261 1/20 0.55
DRD3 P35462 1/20 0.55
OPRK1 P41145 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9364446 0.98 AKR1B1 (0.95) AKR1B1KMT2AADRA2AADRA1AMEN1
Hydrochloric Acid SCHEMBL1374156 0.98 AKR1B1 (0.95) AKR1B1KMT2AADRA2AADRA1AMEN1
SCHEMBL11691926 0.87 AKR1B1 (0.77) AKR1B1KMT2AADRA2AADRA1AMEN1
SCHEMBL29570152 0.86 AKR1B1 (0.74) AKR1B1KMT2AMEN1MAPTKDM4E
SCHEMBL29933615 0.86 AKR1B1 (0.74) AKR1B1KMT2AADRA2AADRA1AMEN1
SCHEMBL13829757 0.86 AKR1B1 (0.74) AKR1B1KMT2AADRA2AADRA1AMEN1
SCHEMBL1285811 0.86 AKR1B1 (0.74) AKR1B1KMT2AMEN1MAPTKDM4E
SCHEMBL3044981 0.86 AKR1B1 (0.74) AKR1B1KMT2AADRA2AADRA1AMEN1
SCHEMBL17410055 0.86 AKR1B1 (0.74) AKR1B1KMT2AADRA2AADRA1AMEN1
SCHEMBL1626950 0.86 AKR1B1 (0.74) AKR1B1KMT2AADRA2AADRA1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454512-B2 Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethenone ELI LILLY AND COMPANY (US) 2025-10-28 US claimed
CN-113993849-B Process and intermediates for preparing 2- (2, 6-dichlorophenyl) -1- [ (1S, 3R) -3- (hydroxymethyl) -5- (3-hydroxy-3-methylbutyl) -1-methyl-3, 4-dihydroisoquinolin-2 (1H) -yl ] ketene 伊莱利利公司 2025-03-07 CN claimed
CN-114994196-B High performance liquid chromatography separation method for guanfacine hydrochloride intermediate 2, 6-dichlorophenylacetic acid and impurities 上海应用技术大学 2024-12-31 CN claimed
EP-3986867-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-(2,6-DICHLOROPHENYL)-1-[(1S,3R)-3-(HYDROXYMETHYL)-5-(3-HYDROXY-3-METHYLBUTYL)-1-METHYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL]ETHENONE LILLY CO ELI (US) 2023-09-13 EP claimed
CN-115028554-B Guanfacine hydrochloride and preparation method thereof 海南慧谷药业有限公司 2023-04-28 CN claimed
CN-115028554-A Guanfacine hydrochloride and preparation method thereof 广东科泰鼎润药业科技有限公司 2022-09-09 CN claimed
CN-114994196-A High performance liquid chromatography separation method for guanfacine hydrochloride intermediate 2,6-dichlorophenylacetic acid and impurities 上海应用技术大学 2022-09-02 CN claimed
US-20220242826-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-(2,6-DICHLOROPHENYL)-1-[(1S,3R)-3-(HYDROXYMETHYL)-5-(3-HYDROXY-3-METHYLBUTYL)-1-METHYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL]ETHENONE ELI LILLY AND COMPANY 2022-08-04 US claimed
CN-114409524-A Preparation method of 2, 6-dichlorophenylacetic acid 上海柏狮生物科技有限公司 2022-04-29 CN claimed
EP-3986867-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-(2,6-DICHLOROPHENYL)-1-[(1S,3R)-3-(HYDROXYMETHYL)-5-(3-HYDROXY-3-METHYLBUTYL)-1-METHYL-3,4-DIHYDROISOQUINOLIN-2(1)-YL]ETHENONE ELI LILLY AND COMPANY (US) 2022-04-27 EP claimed
US-5712307-A Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1998-01-27 US claimed
US-5710178-A ARYL- AND ARYLOXYALKANOIC ACIDS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1998-01-20 US claimed
US-5708025-A BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1998-01-13 US claimed
US-5679799-A Method for producing oxyindoles K-I CHEMICAL INDUSTRY CO., LTD. (JP) 1997-10-21 US claimed
US-5661179-A ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-08-26 US claimed
US-5654333-A THERAPY FOR ANEMIA, CANCER, AIDS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-08-05 US claimed
US-5635532-A ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-06-03 US claimed
US-5635533-A ANTITUMOR AGENTS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-06-03 US claimed
US-5605930-A ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1997-02-25 US claimed
EP-0710648-A1 Method for producing oxyindoles K I CHEMICAL INDUSTRY CO., LTD. (JP) 1996-05-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454512-B2 Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethenone PAM, TLR1, TLR2 AKR1B1 953/4885KMT2A 1763/4885ADRA2A 455/4885
US-20220242826-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-(2,6-DICHLOROPHENYL)-1-[(1S,3R)-3-(HYDROXYMETHYL)-5-(3-HYDROXY-3-METHYLBUTYL)-1-METHYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL]ETHENONE PAM, TLR1, TLR2 AKR1B1 953/4885KMT2A 1763/4885ADRA2A 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.